Peptide·plain sequence-like

ATLPC0027709

DRVYIHP

Routes

Compare in workbench Download release API JSON

Length
7 aa
Monoisotopic mass
898.5 Da
Net charge @ pH 7.4
0.10
Isoelectric point
7.54
GRAVY
-0.771

Coveragecounts only · not riskATLPC0027709

Measurements
20
Endpoints
2
Domains
2/5
Products
—

2 stability measurements
18 clearance measurements
No immunogenicity context
No sequence liability cues

Jump to domain

Open the matching evidence section below

All evidence index · 20

Exposure / Absorption

No evidence

Distribution / Barrier

No evidence

Metabolic & Proteolytic Stability

2 measurements

Excretion / Persistence

18 measurements

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity summaryCanonical sequence only

Identity status: Canonical sequence only
Residues: 7
Peptidoform features: 0
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0030116	—	—	—	Notation only	19

Residue view

Residue display

7 residues

D1R2V3Y4I5H6P7

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

DRVYIHP

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached

3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors7 aa · pI 7.5 · GRAVY -0.77

Length: 7 aa
Monoisotopic mass: 898.47 Da
Average mass: 899.02 Da
Net charge at pH 7.4: 0.10
Estimated pI: 7.54
GRAVY: -0.771
KD-positive residues: 28.6%
Aromatic residues: 14.3%

Developability interpretation

Ionization context: pH 7.4 close to pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 0.37
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

2.96

pH 5

1.08

pH 6

0.77

pH 7.4

0.05

pH 9

-0.79

pH 12

-2.23

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)

1 · 14.3%

Basic (K,R,H)

2 · 28.6%

Hydrophobic aliphatic (A,V,I,L,M)

2 · 28.6%

Aromatic (F,W,Y)

1 · 14.3%

Conformational / sulfur (G,P,C)

1 · 14.3%

Top residues

R114.3%D114.3%H114.3%I114.3%P114.3%Y114.3%V114.3%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

1-7

DRVYIHP

GRAVY -0.771

Most hydrophilic window

1-7

DRVYIHP

GRAVY -0.771

1 local hydropathy window scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

Sequence is shorter than the local amphipathic-window sizes used here.

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

No conservative sequence-liability motifs from the current rule set are present.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 0.37100°/residue · 7 aa

Hydrophobic moment0.37

Mean K-D hydropathy-0.77

Approx. net charge0

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

97.14

Instability index

0.5

At or below 40 — predicted stable in vitro.

Boman index

2.78 kcal/mol

Above 2.48 — elevated potential protein-binding.

Molar extinction coefficient (280 nm)

1,490 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 1.66

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Metabolic & Proteolytic Stability

2 records

How stable is the peptide in biological matrices or protease systems?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeSerum/plasma stability

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability2 records · 2 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	13.8 ± 5.7 Minutes 828 seconds	Eligible when experimental context matches	HPLC · rat · Rats serum	Result: Reported point value · Molecular form: ATLPF0030116 · Dose/window: 100 μM · Rats serum protease · In Vitro · Source: Primary reference linked	Reference
2	0.25 ± 0.05 Hours 900 seconds	Eligible when experimental context matches	Tandem mass spectrometry (MS) · rat · Rats serum	Result: Reported point value · Molecular form: ATLPF0030116 · Dose/window: 100 μM · Rats serum protease · In Vitro · Source: Primary reference linked	Reference

Excretion / Persistence

18 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeHalf Life

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Half Life18 records · 15 matched-context · 3 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	9.2 ± 0.5 Minutes 552 seconds	Eligible when experimental context matches	HPLC · PBS solution containing all three hydrolytic enzymes (0.5 IU/mL), ACE, LAP and NEP	Result: Reported point value · Molecular form: ATLPF0030116 · Dose/window: 0.1 mM · ACE, LAP and NEP · In Vitro · Source: Primary reference linked	Reference
2	24.7 ± 5 Minutes 1482 seconds	Eligible when experimental context matches	LC-MS · CSF	Result: Reported point value · Molecular form: ATLPF0030116 · Route: SC · CSF protease · In Vivo · Source: Primary reference linked	Reference
3	systemic pk half life unspecified phase: 20.9 ± 0.7 Minutes 1254 seconds	Eligible when experimental context matches	LC-MS · rat · Rats serum	Result: Reported point value · Molecular form: ATLPF0030116 · Route: SC · Rats serum protease · In Vivo · Source: Primary reference linked	Reference
4	10 seconds	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of anesthetized spontaneously hypertensive rat	Result: Reported point value · Molecular form: ATLPF0030116 · Dose/window: 10 μg · Time: 30 min · Angiotensin-converting enzyme · in vivo · Source: Primary reference linked	Reference
5	approx 44 seconds	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of anesthetized spontaneously hypertensive rat	Result: Approximate quantitative measurement · Molecular form: ATLPF0030116 · Dose/window: 10 μg · Time: 30 min · Angiotensin-converting enzyme and lisinopril(inhibitor) · in vivo · Source: Primary reference linked	Reference
6	approx 11 seconds	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of anesthetized spontaneously hypertensive rat	Result: Approximate quantitative measurement · Molecular form: ATLPF0030116 · Dose/window: 10 μg · Time: 30 min · Angiotensin-converting enzyme and losartan(AT1 antagonist) · in vivo · Source: Primary reference linked	Reference
7	approx 49 seconds	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of anesthetized spontaneously hypertensive rat	Result: Approximate quantitative measurement · Molecular form: ATLPF0030116 · Dose/window: 10 μg · Time: 30 min · Angiotensin-converting enzyme,losartan(AT1 antagonist)and lisinopril(inhibitor) · in vivo · Source: Primary reference linked	Reference
8	9 seconds	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of mRen-2 transgenic rat	Result: Reported point value · Molecular form: ATLPF0030116 · Dose/window: 10 μg · Time: 30 min · Angiotensin-converting enzyme · in vivo · Source: Primary reference linked	Reference
9	approx 29 seconds	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of mRen-2 transgenic rat	Result: Approximate quantitative measurement · Molecular form: ATLPF0030116 · Dose/window: 10 μg · Time: 30 min · Angiotensin-converting enzyme and lisinopril(inhibitor) · in vivo · Source: Primary reference linked	Reference
10	approx 14 seconds	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of mRen-2 transgenic rat	Result: Approximate quantitative measurement · Molecular form: ATLPF0030116 · Dose/window: 10 μg · Time: 30 min · Angiotensin-converting enzyme and losartan(AT1 antagonist) · in vivo · Source: Primary reference linked	Reference

1–10 / 18

Evidence landscape

20 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

0 evidence records

Distribution / Barrier

0 evidence records

Metabolic & Proteolytic Stability

2 evidence records

Excretion / Persistence

18 evidence records

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Half Life

Serum Plasma Stability

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Matrix / stability

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceMatrixRoute

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Excretion / Persistence Persistence	Half Life	9.2 ± 0.5 Minutes 552 seconds	Reported point value	Eligible when experimental context matches	HPLC · PBS solution containing all three hydrolytic enzymes (0.5 IU/mL), ACE, LAP and NEP	Dose/window: 0.1 mM · Protease: ACE, LAP and NEP · In Vitro	Reference Primary reference linked
2	Excretion / Persistence Persistence	Half Life	24.7 ± 5 Minutes 1,482 seconds	Reported point value	Eligible when experimental context matches	LC-MS · CSF	Route: SC · Protease: CSF protease · In Vivo	Reference Primary reference linked
3	Excretion / Persistence Persistence	Half Life	10 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of anesthetized spontaneously hypertensive rat	Time: 30 min · Dose/window: 10 μg · Protease: Angiotensin-converting enzyme · in vivo	Reference Primary reference linked
4	Excretion / Persistence Persistence	Half Life	approx 14 seconds	Approximate quantitative measurement	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of mRen-2 transgenic rat	Time: 30 min · Dose/window: 10 μg · Protease: Angiotensin-converting enzyme and losartan(AT1 antagonist) · in vivo	Reference Primary reference linked
5	Excretion / Persistence Persistence	Half Life	20.9 ± 0.7 Minutes 1,254 seconds Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE	Reported point value	Eligible when experimental context matches	LC-MS · rat · Rats serum	Route: SC · Protease: Rats serum protease · In Vivo	Reference Primary reference linked
6	Excretion / Persistence Persistence	Half Life	approx 29 seconds	Approximate quantitative measurement	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of mRen-2 transgenic rat	Time: 30 min · Dose/window: 10 μg · Protease: Angiotensin-converting enzyme and lisinopril(inhibitor) · in vivo	Reference Primary reference linked
7	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	0.25 ± 0.05 Hours 900 seconds	Reported point value	Eligible when experimental context matches	Tandem mass spectrometry (MS) · rat · Rats serum	Dose/window: 100 μM · Protease: Rats serum protease · In Vitro	Reference Primary reference linked
8	Excretion / Persistence Persistence	Half Life	0.6 Hours 2,160 seconds Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE	Reported point value	Use only explicitly reported fields	Radioactivity assay · rat · Rats plasma	Route: IV · Dose/window: 4.5 mM · Protease: Rats plasma protease · In Vivo	Reference Primary reference linked
9	Excretion / Persistence Persistence	Half Life	10 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay and HPLC · rat · Blood sample of normotensive Sprague-Dawley rat	Time: 30 min · Protease: Angiotensin-converting enzyme · in vivo	Reference Primary reference linked
10	Excretion / Persistence Persistence	Half Life	6.6 Hours 23,760 seconds Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE	Reported point value	Use only explicitly reported fields	Radioactivity assay · rat · Rats plasma	Route: SC · Dose/window: 4.5 mM · Protease: Rats plasma protease · In Vivo	Reference Primary reference linked

1–10 / 20

Identity & reference map

20 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary4 reference groups

Identity type: canonical sequence
Reported notation: 0
Reference groups: 4
Measurements: 20
ATL peptide ID: ATLPC0027709

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 20

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 20

Different notation

Reported notation does not resolve to the current display sequence.

0 / 20

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

20 / 20

Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity

DRVYIHP

Reported names

No distinct human-readable aliases are exposed.

Reference map4 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	Persistence Half Life	No reported alias	12 identity 12 evidence
Reference Open	Persistence Half Life	No reported alias	3 identity 3 evidence
Reference Open	PersistenceStability Half Life, Serum Plasma Stability	No reported alias	3 identity 3 evidence
Reference Open	PersistenceStability Half Life, Serum Plasma Stability	No reported alias	2 identity 2 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0027709
Identity type: canonical sequence
ADMET endpoints: 2
Evidence records: 20
Reference groups: 4
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0027709

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0027709' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0030116

—

Notation only

Value

Analysis use

Assay / model

Result context

Reference

13.8 ± 5.7 Minutes

828 seconds

Eligible when experimental context matches

HPLC · rat · Rats serum

Result: Reported point value · Molecular form: ATLPF0030116 · Dose/window: 100 μM · Rats serum protease · In Vitro · Source: Primary reference linked